Make sure you’ve read Quantify’s CEO Kirk Geale‘s PharmaTimes article published late last year, explaining how global pharmaceutical executives can harness the power of Scandinavian health data to achieve regulatory and commercial success.

[…]

In Quantify’s latest publication co-authored by Christoph Abé, PhD, the research group conducted a field trial focused on the ICD-11 chapter on mental disorders which contains new diagnoses for impulse control disorders.

Using a vignette-based methodology, this field study […]

To peck someone…again! Luckily in this case, the world of medical coding has us covered with the (hopefully) rare yet precise ICD code W61.32XD “Struck by a chicken, subsequent encounter.”

Although this rare event has a diagnosis code, not all diseases […]

Check out the latest issue of PharmaTimes, where our CEO Kirk Geale explains how global pharmaceutical executives can harness the power of Nordic health data.

Nordic RWD are globally unique and practitioners should not miss the opportunities available in this […]

In our latest publication in the Journal of Medical Economics, the cost-effectiveness of bimekizumab was assessed for the treatment of psoriatic arthritis in Sweden in collaboration with UCB and others.

According to Quantify Research co-author and payer expert Linnea […]

Hopes are high for the first disease modifying treatments in Alzheimer’s disease to be approved on the European market, but many challenges remain. Quantify Research colleagues Anders Gustavsson and Lena Jacobs are […]

Pneumococcal disease (PD) is a major cause of clinical and economic burden worldwide, yet the burden of PD in Swedish adults and its relationship with medical risk factors (MRFs) is largely unknown. In collaboration with MSD,  […]